The use of natural and synthetic phospholipids as pharmaceutical excipients

European Journal of Lipid Science and Technology - Tập 116 Số 9 - Trang 1088-1107 - 2014
Peter van Hoogevest1, Armin Wendel1
1Phospholipid Research Center Heidelberg, Im Neuenheimer Feld 582 Heidelberg, Germany.

Tóm tắt

In pharmaceutical formulations, phospholipids obtained from plant or animal sources and synthetic phospholipids are used. Natural phospholipids are purified from, e.g., soybeans or egg yolk using non‐toxic solvent extraction and chromatographic procedures with low consumption of energy and minimum possible waste. Because of the use of validated purification procedures and sourcing of raw materials with consistent quality, the resulting products differing in phosphatidylcholine content possess an excellent batch to batch reproducibility with respect to phospholipid and fatty acid composition. The natural phospholipids are described in pharmacopeias and relevant regulatory guidance documentation of the Food and Drug Administration (FDA) and European Medicines Agency (EMA). Synthetic phospholipids with specific polar head group, fatty acid composition can be manufactured using various synthesis routes. Synthetic phospholipids with the natural stereochemical configuration are preferably synthesized from glycerophosphocholine (GPC), which is obtained from natural phospholipids, using acylation and enzyme catalyzed reactions. Synthetic phospholipids play compared to natural phospholipid (including hydrogenated phospholipids), as derived from the number of drug products containing synthetic phospholipids, a minor role. Only in a few pharmaceutical products synthetic phospholipids are used. Natural phospholipids are used in oral, dermal, and parenteral products including liposomes. Natural phospholipids instead of synthetic phospholipids should be selected as phospholipid excipients for formulation development, whenever possible, because natural phospholipids are derived from renewable sources and produced with more ecologically friendly processes and are available in larger scale at relatively low costs compared to synthetic phospholipids.Practical applications: For selection of phospholipid excipients for pharmaceutical formulations, natural phospholipids are preferred compared to synthetic phospholipids because they are available at large scale with reproducible quality at lower costs of goods. They are well accepted by regulatory authorities and are produced using less chemicals and solvents at higher yields. In order to avoid scale up problems during pharmaceutical development and production, natural phospholipid excipients instead of synthetic phospholipids should be selected whenever possible.For selection of phospholipid excipients for pharmaceutical formulations, natural phospholipids are preferred compared to synthetic phospholipids because they are available at large scale with reproducible quality at lower costs of goods. They are well accepted by regulatory authorities and are produced using less chemicals and solvents at higher yields. In order to avoid scale up problems during pharmaceutical development and production, natural phospholipid excipients instead of synthetic phospholipids should be selected whenever possible.

Từ khóa


Tài liệu tham khảo

Shurtleff W. Aoyagi A. History of Soy Lecithin http://www.soyinfocenter.com/HSS/lecithin1.php 2007.

Pepeu G., 1990, Phospholipids: Biochemical, Pharmaceutical, and Analytical Considerations [Proceedings of the 5th International Colloquium on Lecithin; Phospholipids: Biochemical, Pharmaceutical, and Analytical Considerations, Held April 10–12, 1989, in Cannes, France], 43

10.1021/mp200479f

Hanin I., 1990, Phospholipids Biochemical, Pharmaceutical, and Analytical Considerations: [Proceedings of the Fifth International Colloquium on Lecithin; Phospholipids: Biochemical, Pharmaceutical, and Analytical Considerations, held April 10–12, 1989, in Cannes, France]

10.3390/molecules14125367

10.1038/sj.cdd.4401168

10.1016/S0163-7827(03)00025-0

Shimojo T., 1974, A method for determination of saturated phosphatidylcholine, J. Lipid Res., 15, 525, 10.1016/S0022-2275(20)36773-0

McFerron W., 2013, Bloomberg L.P.

Bundschuh R. Heinze C. in:Agrarmärkte 2013 Landesanstalt für Entwicklung der Landwirtschaft und der ländlichen Räume (LEL) Bayrische Landesanstalt für Landwirtschaft (LfL) Schwäbisch Gmünd2013 pp.246–274.

Data kindly provided by LIPOID GmbH.

Wendel A., 1995, Kirk‐Othmer Encyclopedia of Chemical Technology, 191

Quinkert R.‐O. Setzer C. Soybean Lecithins and Phospholipids for Pharmaceutical Applications Phospholipid Forschungszentrum e. V./Research Center2010.

Egg Lecithins for Pharmaceutical Application Phospholipid Forschungszentrum e. V./Research Center2008.

10.1016/0024-3205(82)90455-6

Pryde E. H., 1985, Lecithins, 213

European Pharmacopoeia. (Ph. Eur.) 8. 0: 2. 5. 4 Iodine value (reference 01/2008 20504).

Lekim D. The resorption of lecithin administered orally and its physiologic implications in:Soya Lecithin: Nutritional and Clinical Aspects: Proceedings of the First International Colloquium Held in Rome Italy Nov. 22 1980 Cairella M. Lekim D. (Eds.) Societa Editrice Universo Rome1981 pp.21–33.

Xu X., 2008, Phospholipid Technology and Applications, 41

10.1002/3527606033

Bittmann R., 1993, Phospholipids Handbook, 141

Ghyczy M., 1989, Lecithins Sources, Manufacture & Uses, 131

Paltauf F., 1990, Phospholipids Biochemical, Pharmaceutical, and Analytical Considerations: [Proceedings of the Fifth International Colloquium on Lecithin; Phospholipids: Biochemical, Pharmaceutical, and Analytical Considerations, held April 10–12, 1989, in Cannes, France], 1

10.1016/j.nano.2005.06.004

10.1021/js990006q

10.1016/S0166-6851(00)00278-4

Schumann G. Van Hoogevest P. Fankhauser P. Probst A.et al. Comparison of free and liposomal MTP‐PE: Pharmacological and toxicological aspects in:Liposomes in the therapy of infectious diseases and cancer: Proceedings of a Ciba‐Geigy‐Squibb‐UCLA Colloquium held at Lake Tahoe California February 16‐20 1988 Lopez‐Berestein G. Fidler I. J. (Eds.) CIBA‐GEIGY Corporation E.R. Squibb & Sons University of California A.R. Liss New York1989 p.191.

10.1002/anie.198402573

10.1248/cpb.33.572

10.1016/0009-3084(89)90022-4

10.1016/0009-3084(88)90137-5

10.1016/0003-2697(81)90049-X

10.1016/0009-3084(80)90034-1

10.1016/S0040-4020(01)86866-6

Synthetic Phospholipids and Other Synthetic Lipids Corden Pharma Switzerland LLC.

10.1021/ja00310a045

10.1016/0009-3084(81)90039-6

Warner T. G., 1977, An improved method for the preparation of unsaturated phosphatidylcholines: Acylation of sn‐glycero‐3‐phosphorylcholine in the presence of sodium methylsulfinylmethide, J. Lipid Res., 18, 548, 10.1016/S0022-2275(20)41674-8

10.1007/s11095-010-0130-x

10.1016/S1773-2247(11)50001-2

Inactive Ingredient Search for Approved Drug Products U.S. Food and Drug Administration.http://www.accessdata.fda.gov/scripts/cder/iig/index.Cfm

Abelcet RxList Inc.http://www.rxlist.com/abelcet‐drug.htm

AmBisome® (amphotericin B) liposome for injection Astellas Pharma US Inc.www.ambisome.com

Daunoxome (Daunorubicin Citrate) – SummaryDrugLib.com.www.druglib.com/druginfo/daunoxome/

Doxil RxList Inc.www.rxlist.com/doxil‐drug.htm

Assessment report for MEPACT (EMEA/CHMP/635781/2008) European Medicines Agency2008.

Van Hoogevest P. Fankhauser P. An industrial liposomal dosage form for muramyltripeptidephosphatidylethanolamine (MTP‐PE) in:Liposomes in the therapy of infectious diseases and cancer: Proceedings of a Ciba‐Geigy‐Squibb‐UCLA Colloquium held at Lake Tahoe California February 16–20 1988 Lopez‐Berestein G. Fidler I. J. (Eds.) CIBA‐GEIGY Corporation E. R. Squibb & Sons University of California A. R. Liss New York1989 p.453.

Martin F. Liposome Drug Products – Product Evolution and Influence of Formulation on Pharmaceutical Properties and Pharmacology U.S. Food and Drug Administration.

Myocet 50 mg Pulver Dispersion und Lösungsmittel für ein Konzentrat zur Herstellung einer Infusionsdispersion TEVA Pharma B.V.http://www.pharmazie.com/graphic/A/50/0‐90350.pdf2013.

Visudyne® Verteporfin for Injection Valeant Pharmaceuticals North America LLC.http://www.visudyne.com/

Regulon Group.www.regulon.com

Desai N. R. Agha B. J. Kale K. M. US60746662000.

Exparel RxList Inc.http://www.rxlist.com/exparel‐drug.htm

DepoDur RxList Inc.http://www.rxlist.com/depodur‐drug.htm

DepoCyt RxList Inc.http://www.rxlist.com/depocyt‐drug.htm

10.1213/01.ANE.0000145009.03574.78

Cada D. J., 2004, Morphine Sulfate Extended‐Release Liposome Injection

10.1007/s11095-006-9092-4

Intralipid Drugs.com.http://www.drugs.com/pro/intralipid.html

Intralipid 10% RxList Inc.http://www.rxlist.com/intralipid‐10‐drug/indications‐dosage.htm

Diazemuls Emulsion for Injection 5 mg/ml (Diazepam) Actavis Nordic A/S Actavis Group PTC2013.

10.4103/0975-8453.59509

10.1310/hpj4311-903

10.1016/S0939-6411(98)00037-X

Gundermann K.‐J. Schneider E. LipoStabil in:Information Brochure Rhône‐Poulenc Rorer/Nattermann International GmbH1990.

10.1164/ajrccm.155.4.9105072

10.1089/jamp.2010.0855

10.2147/MDER.S16360

WHO Food Additives Series No. 5 World Health Organization1974 p.234.

Commission Regulation (EU) No 231/2012 of March 9 2012 laying down specifications for food additives listed in Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council European Commission 2012.

Annex I of European Parliament and Council Directive No 95/2/EC of February 20 1995 on food additives other than colours and sweeteners European Parliament and Council1995.

Report from the Commission on Dietary Food Additive Intake in the European Union European Commission http://ec.europa.eu/food/fs/sfp/addit_flavor/flav15_en.pdf 2001.

21CFR184.1400 revised as of April 1 2013 U. S. Food and Drug Administration.

21CFR184.1063 August1996 U. S. Food and Drug Administration.

21CFR184.1063 revised as of April 1 2013 U. S. Food and Drug Administration.

Edgren B., 1964, Long‐term tolerance study of two fat emulsions for intravenous nutrition in dogs, Am. J. Clin. Nutr., 14, 28, 10.1093/ajcn/14.1.28

10.1001/archsurg.1961.01300140153029

Schuberth O. W. A. Intravenous Infusion of Fat Emulsions Phosphatides and Emulsifying Agents: Clinical and Experimental Studies(tr.: P.A. Norstedt) Stockh1961.

Mueller J. F., 1967, Fette in der Medizin, 7

Draft Guidance for Industry: Liposome Drug Products Chemistry Manufacturing and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) 2002.

Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed With Reference to an Innovator Liposomal Product (EMA/CHMP/806058/2009/Rev. 02) European Medicines Agency 2013.

European Pharmacopoeia 7.0 general text 5.1.7 Viral Safety.

Commission Regulation (EC) No 1881/2006 of December 19 2006 setting maximum levels for certain contaminants in foodstuffs European Commission2006.

Walts A. E., 1991, Applications of biocatalysts in the synthesis of phospholipids, Chim. Oggi., 9, 29

Walts A. E., 1992, Chirality in industry: the commercial manufacture and applications of optically active compounds, 223

10.1016/0005-2736(93)90105-9

Thông tin
Thông tin xuất bản

European Journal of Lipid Science and Technology

Tập 116 Số 9

1088-1107

Thông tin tác giả